The Impact of Trump’s Drug Price Order: Dissecting the Fallout on Major PBMs
Former President Donald Trump’s recent executive order targeting drug pricing has ignited fierce debate across the healthcare sector, particularly among pharmacy benefit managers (PBMs) like CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx. Issued in late 2023 as part of Trump’s renewed policy push, the order seeks to eliminate controversial rebate practices between PBMs and drug manufacturers—a move analysts warn could disrupt $150 billion in annual pharmaceutical spending while potentially increasing out-of-pocket costs for millions of Americans.
How the Executive Order Reshapes PBM Economics
The order specifically takes aim at the opaque rebate system that has defined PBM operations for decades. Currently, PBMs negotiate discounts (rebates) from drug manufacturers in exchange for favorable formulary placement. However, critics argue these savings rarely reach patients. Trump’s policy would:
- Require PBMs to pass 100% of rebates directly to consumers at the pharmacy counter
- Eliminate “middleman” compensation models tied to drug list prices
- Cap out-of-pocket costs for Medicare Part D beneficiaries
“This is essentially daylight robbery being corrected,” argues healthcare economist Dr. Miriam Kowalski of the Brookings Institution. “PBMs have built empires on spread pricing—paying pharmacies one amount while charging insurers another. The order forces transparency, but the transition won’t be painless.”
Industry data reveals the stakes: PBMs currently manage prescriptions for 266 million Americans and influence 80% of all prescription drug spending. A 2023 Kaiser Family Foundation study found that while rebates averaged 26-30% for brand-name drugs, patients saw only 2-3% in actual cost reductions.
Immediate Market Reactions and PBM Countermoves
Within 72 hours of the order’s announcement, PBM stocks showed notable volatility:
- CVS Health shares dropped 4.2%
- Cigna (Express Scripts parent) fell 5.7%
- UnitedHealth Group declined 3.1%
“The market is pricing in a 15-20% reduction in PBM profitability if this stands,” notes Goldman Sachs healthcare analyst Ethan Blackwell. “These companies will need to fundamentally reinvent their business models—likely shifting toward flat-fee services rather than percentage-based rebates.”
PBMs are already mounting a multifaceted response:
- Lobbying efforts: The Pharmaceutical Care Management Association has deployed 47 registered lobbyists to Capitol Hill
- Legal challenges: Preliminary filings suggest arguments about regulatory overreach
- Operational pivots: CVS recently announced a new “transparent pricing model” pilot program
Patient Impacts: Promise vs. Potential Pitfalls
Proponents argue the order could save Medicare beneficiaries $32 billion over 10 years according to Congressional Budget Office projections. Diabetes patient advocate Ryan Nguyen shares cautious optimism: “When my insulin co-pay jumped from $30 to $300 last year, the PBM blamed the manufacturer. Now we’ll see who was really profiting.”
However, health policy experts warn of unintended consequences:
- Insurers may raise premiums to offset lost rebate revenue
- Smaller pharmacies could face cash flow crises as reimbursement models change
- Drug manufacturers might increase list prices to maintain margins
A recent Avalere Health analysis suggests the order could initially increase Part D premiums by 12-18% before potential long-term savings materialize.
The Road Ahead: Legal, Political, and Industry Crossroads
The order’s implementation faces significant hurdles:
- Legal challenges: Multiple lawsuits are expected regarding HHS authority
- Election-year dynamics: Biden administration may modify or rescind the order
- Global implications: International drug pricing models could influence U.S. negotiations
As PBMs prepare for what Cigna CEO David Cordani called “the most transformative moment since the Medicare Modernization Act,” industry observers suggest watching three key indicators:
- Q2 2024 earnings calls for PBM margin guidance
- State-level legislation mimicking the federal order
- Formulary changes during the 2025 plan year bidding process
For consumers navigating these changes, experts recommend reviewing plan documents carefully and consulting independent pharmacists about emerging cost-saving alternatives. As the dust settles on this seismic policy shift, one truth becomes clear: the era of opaque drug pricing may finally be ending—but the path forward remains uncertain for all stakeholders in America’s complex healthcare ecosystem.
See more WebMD Network
